- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Publication
Video
Dermatology Times
Drug Watch: What's Coming in the Rosacea Pipeline
Author(s):
Dermatology Times® interviews editorial board member Richard Gallo, MD, PhD, who dives into what is currently lacking is rosacea patient care, how the new mechanisms of action of these potential treatments will better address current struggles, and more.
Dermatology Times® interviews editorial board member Richard Gallo, MD, PhD, chair of dermatology at the University of California-San Diego, in San Diego, California, about what's happening in the rosacea drug pipeline. In this video interview, Gallo talks about what's new in treatment, how certain rosacea phenotypes are harder to treat than others, and what is being done to addresss these issues.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
